Sulpiride in Tardive Dyskinesia

J. Gerlach, D. E. Casey

Research output: Contribution to journalArticlepeer-review

28 Scopus citations


Abstract The pathogenesis of tardive dyskinesia (TD) appears to consist of a combination of a predisposing vulnerability of the patient and an antidopaminergic (neuroleptic) treatment. This combination may result in 1) a relative dopamine hyperreactivity associated with an increased number of dopamine receptors and/or a cholinergic hypo‐function (reversible TD), and 2) in long‐term treatment, degenerative phenomena leading to a decreased threshold for expressing dyskinetic symptoms (irreversible TD). Sulpiride, a selective D‐2 dopamine receptor blocker, is able to suppress TD without producing a reciprocal aggravation in parkinsonism, although in vulnerable patients it may induce/aggravate parkinsonian symptoms. Animal data suggest that sulpiride has less TD‐inducing effect than traditional neuroleptics, but long‐term clinical studies are still needed to prove this suggestion.

Original languageEnglish (US)
Pages (from-to)93-102
Number of pages10
JournalActa Psychiatrica Scandinavica
Issue number311 S
StatePublished - Jan 1984
Externally publishedYes


  • Sulpiride
  • substituted benzamides.
  • tardive dyskinesia

ASJC Scopus subject areas

  • Psychiatry and Mental health


Dive into the research topics of 'Sulpiride in Tardive Dyskinesia'. Together they form a unique fingerprint.

Cite this